3 Healthcare Stocks You Should "Keep an Eye" On

NYSE: GKOS | Glaukos Corporation  News, Ratings, and Charts

GKOS – Eye healthcare will always be in demand. Here are three eye stocks worth a look: Glaukos Corporation (GKOS), Kala Pharmaceuticals (KALA), and Ocular Therapeutix (OCUL).

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

If you are struggling to predict the course of the stock market, you’re not alone. We are living through one of the more tumultuous eras in human history, yet the market continues to inch upward in quite a surprisingly steady manner.

There is much discussion as to which stock market sectors are relatively safe. Some point to precious metals as safe havens. Others insist the technology is the only current sure bet. However, it appears that healthcare is a relatively safe place to park hard-earned money as the pandemic pays out.

If you are willing to tolerate the slight risk posed by healthcare stocks, you might emerge from this period of market undulation with a sizable profit. Savvy investors should give serious consideration to these three intriguing publicly-traded eye care companies: Glaukos Corporation (GKOS), Kala Pharmaceuticals (KALA), Ocular Therapeutix (OCUL), and EyePoint Pharmaceuticals (EYPT).

Glaukos Corporation (GKOS)

No matter what direction the economy goes in the near future and across posterity, ophthalmic medical technology will still be in significant demand. After all, we all need a pair of functioning eyes to enjoy life to the fullest. GKOS works to create and commercialize novel surgical devices along with therapies for the treatment of glaucoma.

In our exclusive POWR Ratings, GKOS has an A for Industry Rank and is ranked near the top half of the Medical – Devices & Equipment industry.

Currently, GKOS is priced at slightly more than half of its 52-week high of $79.97. However, the stock has steadily climbed upward since dipping to $25 in March. GKOS is likely to beat earnings in the quarter to come, setting the stage for a meaningful uptick as we transition to the end of summer.

Kala Pharmaceuticals (KALA)

Nanotechnology will make waves in the future as tiny computers delve into the human body to reveal health and wellness information. Diminutive computer chips will even be used for medical operations. KALA creates and commercializes therapeutics with nanoparticle technology. KALA’s drugs are delivered into mucosal tissue within the eyes and the lungs and other parts of the body.

The POWR Ratings reveal KALA has an Industry Rank of A. The average analyst price target is $21.50, which 137% higher than its current price.

Out of the half dozen analysts who have studied the stock, every one of them rates it as a Buy. KALA progressed upward since spring, reaching $13 at the start of summer only for profit-taking to bring the stock down below $10. Look for a potential bounce back in the weeks and months to come.

Ocular Therapeutix (OCUL)

A wide array of technologies are emerging to improve human health, including ophthalmology. OCUL relies on hydrogel technology to help those with ocular health challenges. This Bedford, MA based company has fantastic POWR Ratings grades. OCUL has a grade of A in Peer Grade and Trade Grade, and a B in Buy & Hold Grade and Industry Rank. OCUL is ranked #42 out of 338 Biotech stocks.

Analysts remain bullish on OCUL, setting an average price target of $12.67. Over the last year, OCUL has had a relentless upward trend that is likely to continue for the rest of the year.

OCUL’s Dextensza product that treats eye inflammation in the aftermath of eye surgery has proven to be quite the success story. This is meaningful as the existing market for treating pain stemming from eye surgery is sizable. OCUL’s Dextenza product may eventually rake in $500 million or possibly even a billion dollars.

Want More Great Investing Ideas?

9 “BUY THE DIP” Growth Stocks for 2020

How HIGH Can This Tech Bubble Fly?

7 “Safe-Haven” Dividend Stocks for Turbulent Times


GKOS shares were trading at $46.84 per share on Monday afternoon, up $3.14 (+7.19%). Year-to-date, GKOS has declined -14.01%, versus a 3.17% rise in the benchmark S&P 500 index during the same period.


About the Author: Patrick Ryan


Patrick Ryan has more than a dozen years of investing experience with a focus on information technology, consumer and entertainment sectors. In addition to working for StockNews, Patrick has also written for Wealth Authority and Fallon Wealth Management. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
GKOSGet RatingGet RatingGet Rating
KALAGet RatingGet RatingGet Rating
OCULGet RatingGet RatingGet Rating

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Do NOT Buy Stocks Before the Election!

The 2 months coming into a Presidential election are traditionally rough for the stock market (SPY). The great uncertainty leads to a selloff that begets a rally after the election is finalized. But if the increase in write in ballots delays election results, then you can imagine how much more uncertainty there will be...and how much worse that is for the market.

:  |  News, Ratings, and Charts

Should You Buy Palantir’s Direct Listing?

Palantir (PLTR) is a highly anticipated startup that creates software to help governments and businesses find insights out of large data sets. The stock shares some characteristics with recent big IPO winners like high growth, margins, and annual recurring revenue.


:  |  News, Ratings, and Charts

2 Election Stocks for a Biden Win and 2 for a Trump Win

The first presidential debate is tonight and while the debate itself isn't likely to move markets, we do need to start considering stocks that would benefit under each candidate. Here are two stocks that should benefit from a Biden win, Tesla (TSLA) and UnitedHealth (UNH), and two that should benefit from a Trump win, Northrop Grumman (NOC) and Exxon Mobil (XOM).

:  |  News, Ratings, and Charts

Should You Buy the Asana Direct Listing?

Asana (ASAN) is going public with a direct listing. The company builds workplace collaboration tools that are growing in popularity. It has 2/3 of the Fortune 500 companies using its product, and it has a successful track record of monetizing users.

:  |  News, Ratings, and Charts

2 Election Stocks for a Biden Win and 2 for a Trump Win

The first presidential debate is tonight and while the debate itself isn't likely to move markets, we do need to start considering stocks that would benefit under each candidate. Here are two stocks that should benefit from a Biden win, Tesla (TSLA) and UnitedHealth (UNH), and two that should benefit from a Trump win, Northrop Grumman (NOC) and Exxon Mobil (XOM).

Read More Stories

More Glaukos Corporation (GKOS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GKOS News